IMCR

Immunocore Holdings PLC

Add to Watchlist

Advanced Chart

33.500

-0.41(-1.209%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

34.610

Open

33.890

VWAP

Vol

312.39K

Mkt Cap

1.68B

Low

33.025

Amount

EV/EBITDA(TTM)

Total Shares

50.01M

1.26B

EV/OCF(TTM)

40.47

P/S(TTM)

5.21

Immunocore Holdings plc is a United Kingdom-based commercial-stage biotechnology company. The Company is engaged in the development of TCR bispecific immunotherapies, ImmTAX, which immunes mobilizing monoclonal TCRs Against X disease, designed to treat a range of diseases, including cancer, autoimmune and infectious disease. The Company has a clinical-stage pipeline of wholly owned and partnered programs across three different therapeutic areas: oncology, infectious diseases, and autoimmune and inflammation diseases. Its lead product, KIMMTRAK, is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma (mUM), in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include IMC-F106C, IMC-F115C, IMC-F119C, IMC-F117C, IMC-F113V, IMC-I109V, IMC-SII8AI, among others. Its clinical programs are being conducted with patients with a range of cancers including melanoma, lung, gastric and others.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

97.96M

+16.55%

-0.259

-44.93%

96.73M

+20.54%

-0.197

-216.11%

93.14M

+23.52%

-0.162

-29.5%

Estimates Revision

The market is revising Upward the revenue expectations for Immunocore Holdings plc (IMCR) for FY2025, with the revenue forecasts being adjusted by 5.18% over the past three months. During the same period, the stock price has changed by 11.30%.

Revenue Estimates for FY2025

Revise Upward

+5.18%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-57.96%

In Past 3 Month

Stock Price

Go Up

+11.30%

In Past 3 Month

8 Analyst Rating

99.25% Upside

Wall Street analysts forecast IMCR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMCR is 66.75 USD with a low forecast of 33.00 USD and a high forecast of 100.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

7 Buy

1 Hold

0 Sell

Strong Buy

99.25% Upside

Current: 33.500

Low

33.00

Averages

66.75

High

100.00

99.25% Upside

Current: 33.500

Low

33.00

Averages

66.75

High

100.00

Deutsche Bank

initiated

$65

2025-05-27

Reason

Deutsche Bank

Price Target

$65

2025-05-27

initiated

Reason

Deutsche Bank initiated coverage of Immunocore with a Buy rating and $65 price target. The firm says Kimmtrak has established itself as the standard of care for HLA-A*02+ front-line metastatic uveal melanoma with its overall survival benefit. Immunocore's current valuation offers a favorable risk/reward where Kimmtrak's "niche" in metastatic uveal melanoma provides a "floor valuation" with expansion into second-line cutaneous melanoma providing upside, the analyst tells investors in a research note.

Oppenheimer

Outperform

maintain

$85 -> $86

2025-05-08

Reason

Oppenheimer

Price Target

$85 -> $86

2025-05-08

maintain

Outperform

Reason

Oppenheimer raised the firm's price target on Immunocore to $86 from $85 and keeps an Outperform rating on the shares. The firm notes that on Wednesday, the company announced strong Q1 sales for KIMMTRAK, with revenue of $93.9M vs. OPCO/Consensus of $88M/$87M, +12% from the prior quarter.

JP Morgan

Jessica Fye

Buy

Maintains

$54 → $50

2025-04-14

Reason

JP Morgan

Jessica Fye

Price Target

$54 → $50

2025-04-14

Maintains

Buy

Reason

Needham

Gil Blum

Strong Buy

Reiterates

$71

2025-04-10

Reason

Needham

Gil Blum

Price Target

$71

2025-04-10

Reiterates

Strong Buy

Reason

Mizuho

Graig Suvannavejh

Hold

Maintains

$38 → $33

2025-04-07

Reason

Mizuho

Graig Suvannavejh

Price Target

$38 → $33

2025-04-07

Maintains

Hold

Reason

Mizuho lowered the firm's price target on Immunocore to $33 from $38 and keeps a Neutral rating on the shares. The firm's thesis on Immunocore remains unchanged, and while Mizuho views Immunocre as a pioneer and leader in the development of T-cell receptor-based therapeutics for cancer, overall lack of meaningful clinical newsflow over the next 12-15 months for the company makes it difficult to see why its shares should outperform.

HC Wainwright & Co.

Patrick Trucchio

Strong Buy

Reiterates

$100

2025-03-12

Reason

HC Wainwright & Co.

Patrick Trucchio

Price Target

$100

2025-03-12

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Immunocore Holdings PLC (IMCR.O) is -44.63, compared to its 5-year average forward P/E of -44.81. For a more detailed relative valuation and DCF analysis to assess Immunocore Holdings PLC 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-44.81

Current PE

-44.63

Overvalued PE

19.89

Undervalued PE

-109.51

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-60.37

Current EV/EBITDA

-18.66

Overvalued EV/EBITDA

82.78

Undervalued EV/EBITDA

-203.51

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

16.50

Current PS

4.56

Overvalued PS

32.42

Undervalued PS

0.57

Financials

Annual

Quarterly

FY2025Q1

YoY :

+33.16%

93.88M

Total Revenue

FY2025Q1

YoY :

-86.35%

-3.62M

Operating Profit

FY2025Q1

YoY :

-120.56%

5.02M

Net Income after Tax

FY2025Q1

YoY :

-120.41%

0.10

EPS - Diluted

FY2025Q1

YoY :

-102.73%

137.00K

Free Cash Flow

FY2025Q1

YoY :

-0.54%

99.11

Gross Profit Margin - %

FY2025Q1

YoY :

-237.74%

7.81

FCF Margin - %

FY2025Q1

YoY :

-115.44%

5.35

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

24.0M

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

2.4M

Volume

Months

6-9

1.8M

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

24.0M

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

IMCR News & Events

Events Timeline

2025-05-07 (ET)

2025-05-07

07:15:39

Immunocore reports Q1 EPS 10c, consensus (40c)

2025-02-26 (ET)

2025-02-26

07:09:21

Immunocore reports Q4 EPS (47c), consensus (16c)

2025-01-10 (ET)

2025-01-10

06:25:33

Immunocore reports cash, equivalents of $820M as of December 31

News

7.5

06-30Globenewswire

Er-Kim Announces Exclusive Agreement with Immunocore to Distribute KIMMTRAK in Turkey, and the MENA, Caucasus and CIS Regions

9.0

06-23NASDAQ.COM

FDA Extends INCY's Application for Opzelura Label Expansion

8.5

06-20NASDAQ.COM

CureVac Soars 41% in a Month on a $1.25B Buyout Offer From BioNTech

People Also Watch

Dyne Therapeutics Inc

Viridian Therapeutics Inc

Universal Technical Institute Inc

Goldman Sachs BDC Inc

FAQ

What is Immunocore Holdings PLC (IMCR) stock price today?

The current price of IMCR is 33.5 USD — it has decreased -1.21 % in the last trading day.

IMCR

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

IMCR News & Events

Events Timeline

News

People Also Watch

FAQ

What is Immunocore Holdings PLC (IMCR) stock price today?

What is Immunocore Holdings PLC (IMCR)'s business?

What is the price predicton of IMCR Stock?

What is Immunocore Holdings PLC (IMCR)'s revenue for the last quarter?

What is Immunocore Holdings PLC (IMCR)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Immunocore Holdings PLC (IMCR)'s fundamentals?

How many employees does Immunocore Holdings PLC (IMCR). have?

What is Immunocore Holdings PLC (IMCR) market cap?